Ypsomed is betting big that more people will treat chronic conditions at home, using connected self-injection devices that drug makers increasingly prefer to outsource. The upside comes from its deep partnerships and broad device lineup, but heavy spending and price pressure could test whether those gains really stick.Read more
Ypsomed is reshaping itself into a behind-the-scenes partner for drug companies, betting that a tighter focus and new factories closer to key markets can make the business more efficient. The upside comes from a busy pipeline of new drug delivery projects, but big expansion plans and reliance on a few markets could make results choppier than they look.Read more
Ypsomed is spending heavily to expand its manufacturing, but that bet could backfire if demand for injectable drug devices cools or big partners change course. At the same time, tougher healthcare rules and fast-moving digital competitors could squeeze pricing and make today’s products feel dated.Read more
No trending discussion available.
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
